Search

The presence of pharmaceuticals in effluents, which are wastewater discharges from various sources, has emerged as a significant environmental concern in recent years. Among the various methods available to address this challenge, adsorption stands out as one of the most effective, both technically and economically. In this study, we investigate the potential of cross-linked chitosan (C-CHIT) as an adsorbent for sodium cromoglicate (CG) and sodium diclofenac (DF). Both CG and DF were found to spontaneously adsorb onto C-CHIT, a sorbent with a positively charged surface when dispersed in water (as confirmed by zeta potential measurements). The adsorption of these anionic drugs resulted in a change in the polarity of the surface charge. Thermodynamic analysis was conducted using a standard approach, wherein parameters from Redlich–Peterson and Frumkin isotherms at the low-concentration limit were utilized to calculate the enthalpy and entropy of adsorption. This analysis suggested that CG was more effectively adsorbed onto C-CHIT. Additionally, a novel approach was proposed in this study for adsorption under surface saturation conditions, which deviate from ideal solution conditions. Interestingly, thermodynamic data indicated a reversal of behavior, with DF being more effectively adsorbed by C-CHIT. This finding was supported by geometric parameters calculated using MarvinSketch 23.12, along with a more repulsive Frumkin's lateral interaction parameter for CG. [ABSTRACT FROM AUTHOR]

Understanding the transport mechanism is crucial for developing inhibitors that block allergen absorption and transport and prevent allergic reactions. However, the process of how beta-conglycinin, the primary allergen in soybeans, crosses the intestinal mucosal barrier remains unclear. The present study indicated that the transport of beta-conglycinin hydrolysates by IPEC-J2 monolayers occurred in a time- and quantity-dependent manner. The beta-conglycinin hydrolysates were absorbed into the cytoplasm of IPEC-J2 monolayers, while none were detected in the intercellular spaces. Furthermore, inhibitors such as methyl-beta-cyclodextrin (MβCD) and chlorpromazine (CPZ) significantly suppressed the absorption and transport of beta-conglycinin hydrolysates. Of particular interest, sodium cromoglycate (SCG) exhibited a quantity-dependent nonlinear suppression model on the absorption and transport of beta-conglycinin hydrolysates. In conclusion, beta-conglycinin crossed the IPEC-J2 monolayers through a transcellular pathway, involving both clathrin-mediated and caveolae-dependent endocytosis mechanisms. SCG suppressed the absorption and transport of beta-conglycinin hydrolysates by the IPEC-J2 monolayers by a quantity-dependent nonlinear model via clathrin-mediated and caveolae-dependent endocytosis. These findings provide promising targets for both the prevention and treatment of soybean allergies. [ABSTRACT FROM AUTHOR]

Khellin is the key furanocoumarin of Ammi visnaga L. (Lam.) that exhibits various biological properties. This unique natural product has inspired the discovery of two first-in-class drugs, amiodarone and sodium cromoglycate. A wide range of analytical methods were generated while translating khellin scaffold into clinically used drugs; however, they have never been reviewed and critically assessed. The present review aims to review and evaluate the analytical techniques for the natural products, khellin, visnagin, and their inspired drugs, amiodarone and sodium cromoglycate. High-performance liquid chromatography (HPLC) is the extensively used technique in most analytical methods reported for these compounds; however, other techniques including the fluorimetry, luminescence spectrophotometry, potentiometry, voltammetry, FT-Raman spectroscopy, and ELISA were also employed. The review will be helpful for further basic and translational research on furanochromone and related scaffolds. [ABSTRACT FROM AUTHOR]

Understanding the transport mechanism is crucial for developing inhibitors that block allergen absorption and transport and prevent allergic reactions. However, the process of how beta-conglycinin, the primary allergen in soybeans, crosses the intestinal mucosal barrier remains unclear. The present study indicated that the transport of beta-conglycinin hydrolysates by IPEC-J2 monolayers occurred in a time- and quantity-dependent manner. The beta-conglycinin hydrolysates were absorbed into the cytoplasm of IPEC-J2 monolayers, while none were detected in the intercellular spaces. Furthermore, inhibitors such as methyl-beta-cyclodextrin (MβCD) and chlorpromazine (CPZ) significantly suppressed the absorption and transport of beta-conglycinin hydrolysates. Of particular interest, sodium cromoglycate (SCG) exhibited a quantity-dependent nonlinear suppression model on the absorption and transport of beta-conglycinin hydrolysates. In conclusion, beta-conglycinin crossed the IPEC-J2 monolayers through a transcellular pathway, involving both clathrin-mediated and caveolae-dependent endocytosis mechanisms. SCG suppressed the absorption and transport of beta-conglycinin hydrolysates by the IPEC-J2 monolayers by a quantity-dependent nonlinear model via clathrin-mediated and caveolae-dependent endocytosis. These findings provide promising targets for both the prevention and treatment of soybean allergies.

Objective To discuss the effect of sodium cromoglycate (SCG) on the neural function and cognitive function in the rats with cerebral ischemic stroke (CIS), and to clarify its mechanism. Methods A total of 80 male SD rats were selected and 18 were randomly selected as sham operation group. The remaining rats were constructed the cerebral ischemia/reperfusion (I/R) injury models by thread embolization method. The 45 successful modeling rats were randomly divided into I/R group, I/R + low dose of SCG group, and I/R +high dose of SCG group (n=15) .At 24 h after modeling, the rats in I/R+low dose of SCG group and I/R +high dose of SCG group were intraperitoneally injected with 20 and 60 mg·kg－1 SCG for 2 weeks, respectively. The neurological scores of the rats in various groups were evaluated by modified neurological severity score (mNSS) criterion； the area of cerebral infarction was detected by using 2, 3, 5-triphenyltetrazolium chloride (TTC) staining；the Y-maze experiment was used to detect the memory abilities of the rats in various groups；electrophysiological measurement was used to analyze the accurate reaction rate, accurate reaction time, and field excitatory postsynaptic potential (fEPSP) slopes of the rats in various groups；Golgi staining was used to detect the morphology of dendritic spines in dentate gyrus of hippocampus in brain tissue of the rats in various groups；immunofluorescence method was used to detect the numbers of 5-bromodeoxyuridine (BrdU) positive cells and the expression levels of doublecortin (DCX) protein in dentate gyrus of hippocampus in brain tissue of the rats in various groups； Western blotting method was used to detect the expression levels of brain-derived neurotrophic factor (BDNF), tyrosine kinase B receptor (TrkB), neurotrophin 3 (NT-3), and tyrosine kinase C receptor (TrkC) proteins in brain tissue of the rats in various groups. Results Compared with sham operation group, the neurological score and the cerebral infarction area of the rats in I/R group were increased (P<0.05), the accurate reaction rate was decreased (P<0.05), and the accurate reaction time was increased (P<0.05), the fEPSP slope and the density of dendritic spine was decreased (P<0.05), the number of BrdU positive cells in dentate gyrus of hippocampus in brain tissue and the expression level of DCX protein in hippocampus tissue had no significant differences (P>0.05), and the expression level of NT-3 protein in hippocampus tissue was increased (P<0.05), but the expression levels of BNDF, TrkB, and TrkC proteins had no significant differences (P>0.05) . Compared with I/R group, the neurological scores of the rats in I/R+high dose of SCG group was decreased (P<0.05), the infarction area was decreased (P<0.05), the accurate reaction rate was increased (P<0.05), the accurate reaction time was decreased (P<0.05), the fEPSP slope and the dendritic spine density were increased (P<0.05), the number of BrdU positive cells and the expression level of DCX protein in dentate gyrus of hippocampus in the brain tissue were increased (P<0.05), and the expression levels of BDNF, TrkB, NT-3, and TrkC proteins were significantly increased (P<0.05) . Conclusion SCG has the protective effect on the neurological and cognitive functions in the I/R model rats and its mechanism may be related to the increasing of the expressions of BDNF/TrkB and NT-3/TrkC signaling pathway related proteins and promoting the proliferation of the neurons. [ABSTRACT FROM AUTHOR]

Background. Mast cells are immune cells that mediate hypersensitivity and allergic reactions in the body, secreting histamine and other inflammatory molecules. They have been associated with different inflammatory conditions such as obesity and other adipose tissue disorders. Lipedema is a chronic disease characterized by an abnormal accumulation of adipose tissue on the legs and arms, pain, and other symptoms. Mast cells may play a role in the pathology of lipedema. Objective. Pilot study to determine levels of histamine and its metabolites in lipedema subcutaneous adipose tissue (SAT) biopsy samples, and to test sodium cromoglycate for the treatment of mast cells in women with lipedema. Methods. Biopsies from lipedema and control SAT were collected and analyzed histologically for the presence of mast cells. Mass spectrometry was used to measure the levels of histamine, a key marker of mast cells, and its metabolites in SAT in women with lipedema and controls, and after a group of women with lipedema were administered oral and topical doses of sodium cromoglycate for two weeks. Results. Histological examination of biopsies from lipedema patients confirmed the presence of mast cells. Metabolomic analysis revealed high levels of histamine and its metabolites in samples from women with lipedema compared to controls. Following a two-week treatment period, lipedema tissue samples exhibited reduced levels of histamine, suggesting a reduction of mast cell activity. Conclusion. Sodium cromoglycate has the ability to stabilize mast cells and reduce histamine levels in lipedema patients, which could be useful in lowering the symptoms of lipedema. [ABSTRACT FROM AUTHOR]

This article presents the results of studies of the levels of expression of the IL13R gene and the levels of expression of the molecular IL13R in the bronchi of control rats and rats with ovalbumin-induced asthma. The choice of these receptors is due to the great importance of these structures in the pathogenesis of allergic bronchial asthma. Biological materials of 64 Wistar rats were studied using real-time PCR and immunohistochemical methods. As a result of the studies, it was found that under conditions of asthma development in the tissues of the bronchi of rats, a pronounced expression of the IL13R genes, a significant expression of the molecular receptor for interleukin-13, occurs. In bronchi with an intramural ganglion (bifurcation zone), the level of IL13R gene expression and the level of expression of the IL13R molecular receptor were significantly higher than in tracheal samples without ganglia. Sodium cromoglycate, administered to rats 5 hours after the last inhalation of ovalbumin, led to a decrease in the mRNA content in the bronchi of animals compared to animals that did not receive mast cell stabilizer treatment. [ABSTRACT FROM AUTHOR]

Sodium hyaluronate (SHA) is an anti-inflammatory and protective agent against bronchoconstriction, and sodium cromoglicate (SCG) prevents exercise-induced bronchoconstriction and inflammation. Based on the pharmacological properties of both substances, this study aimed to develop a dry powder inhaler (DPI) of SHA alone and in combination with SCG. The target of the study was to develop flowable formulations without any surfactants by using the spray drying method. To obtain respirable SHA and SCG:SHA particles, variables of the spray dryer, such as inlet temperature, atomized air flow, and feed solution, were changed. The particles 1–8 μm in size were produced with high yield by spray drying and increasing the ethanol percentage of the feed solution (60%), which is the most remarkable parameter. After that, physicochemical characterizations were performed. The aerosol performance of DPI formulations prepared using lactose was evaluated using Handihaler® DPI. The fine particle fraction (FPF) was 36% for the SHA formulation, whereas it was 52 and 53% for SCG and SHA, respectively, in the SCG:SHA formulation. Consequently, both particles were produced reproducibly by spray drying, and inhaled SHA and SCG:SHA dry powder formulations were developed due to their high FPF and flowability with lactose. [ABSTRACT FROM AUTHOR]

IntroductionBullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease which mainly affects the elderly. It manifests as severe pruritus, urticarial plaques, and tense bullae and is associated with significant mortality. Therapy options for itch in BP patients are limited, mainly because the pathogenesis of itch in BP remains unclear. Sodium cromoglycate was commonly used in the past as an inhaled drug for the management of bronchial asthma and as an oral treatment for children with urticaria pigmentosa. In this study we sought to assess its efficacy in reducing BP associated itch.ObjectiveAssessing the efficacy of oral sodium cromoglycate in reducing BP-related pruritus after stabilization of disease activity.MethodsWe retrospectively reviewed the medical records of patients with a confirmed diagnosis of BP who were treated with sodium cromoglycate. Patient reported outcome measures (PROM) including: BPDAI pruritus, ABQOL and TABQOL, and BPDAI activity score were compared at two points in time: before commencing treatment with sodium cromoglycate or before commencing maximal dose of this treatment, and at least 4 weeks after treatment commencement.ResultsA total of 21 patients met the inclusion criteria. After at least 4 weeks of treatment with oral sodium cromoglycate BPDAI pruritus, ABQOL and TABQOL scores were statistically significantly decreased compared to the scores prior to treatment commencement, P < 0.000, P < 0.008, and P < 0.004, respectively.DiscussionOral treatment with sodium cromoglycate for the management of pruritus in BP patients may be beneficial, however, further prospective studies are required to better assess its efficacy.

The aim of this work was to study the effect of gas microbubbles on the production of particles suitable for inhalatory administration by a spray drying technology. An antiasthmatic model drug (sodium cromoglycate) was selected in order to evaluate the effect of different gases (air, CO2 and N2) and spray drying operating conditions on the particles aerosolization performance. To this end, gas supersaturated aqueous drug solutions were obtained in a pressurized vessel and then processed by spray drying. The process yield, morphology, size, bulk and tap densities, moisture content and aerosolization properties of the particles were evaluated. The presence of microbubbles in the spray drying feed led to powders with smaller mean geometric sizes than particles obtained without bubbles. The gas-water solubility emerged as a key parameter to obtain inhalatory particles with good aerosolization properties. High water-soluble gases led to bigger particles, while low soluble ones allow to produce smaller particles. The use of air (with an intermediate water solubility respect to CO2 and N2) and an adequate set of spray drying operating conditions allowed to obtain sodium cromoglycate particles with superior aerosolization properties than a commercial formulation. Overall, a novel, simple and low-cost method to produce inhalatory particles with excellent aerosolization properties was developed by supersaturating the spray drying liquid feed without using pore-forming agents during the production step, or carriers in the final formulation. [ABSTRACT FROM AUTHOR]

PURPOSE: This study aimed to assess the efficacy and safety of sodium cromoglycate with fluorometholone in patients with allergic conjunctivitis. METHODS: We conducted a single-arm phase IV open-label trial where fifty patients who received the eye drops were followed for 4 weeks. Treatment efficacy was assessed using the ocular itching score, conjunctival assessment score, total symptom and sign (TSS) score, and Visual Analog Scale (VAS). RESULTS: Patients who received sodium cromoglycate-fluorometholone eye drops experienced significant improvements in their ocular itching score (mean difference [MD]: 1.14, P = 0.001) and conjunctival redness score (MD: 1.18, P = 0.001). Statistically significant improvements in TSS and VAS were achieved in 78% of the patients reporting no conjunctivitis by the end of the study. The overall therapeutic response to the drug was as follows: 16% improved and 84% much improved. No serious adverse events were reported. CONCLUSION: Sodium cromoglycate with fluorometholone eye drops achieved 100% therapeutic response among patients with allergic conjunctivitis. The eye drops improve the ocular itching, and conjunctival irritation without serious adverse events. This combination appears effective and tolerable for treatment of allergic conjunctivitis. [ABSTRACT FROM AUTHOR]

Background: Mast cells are immune cells that mediate hypersensi-tivity and allergic reactions in the body, secreting histamine and other inflammatory molecules. They have been associated with different inflammatory conditions such as obesity and other adipose tissue di-sorders. Lipedema is a chronic disease characterized by an abnormal accumulation of adipose tissue on the legs and arms, pain, and other symptoms. Mast cells may play a role in the pathology of lipedema., Objective: Pilot study to determine levels of histamine and its metabolites in lipedema subcutaneous adipose tissue (SAT) biopsy samples, and to test sodium cromoglycate for the treatment of mast cells in women with lipedema., Methods: Biopsies from lipedema and control SAT were collected and analyzed histologically for the presence of mast cells. Mass spec-trometry was used to measure the levels of histamine, a key marker of mast cells, and its metabolites in SAT in women with lipedema and controls, and after a group of women with lipedema were administered oral and topical doses of sodium cromoglycate for two weeks., Results: Histological examination of biopsies from lipedema patients confirmed the presence of mast cells. Metabolomic analysis revealed high levels of histamine and its metabolites in samples from women with lipedema compared to controls. Following a two-week treatment period, lipedema tissue samples exhibited reduced levels of histamine, suggesting a reduction of mast cell activity., Conclusion: Sodium cromoglycate has the ability to stabilize mast cells and reduce histamine levels in lipedema patients, which could be useful in lowering the symptoms of lipedema.

Introduction: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease which mainly affects the elderly. It manifests as severe pruritus, urticarial plaques, and tense bullae and is associated with significant mortality. Therapy options for itch in BP patients are limited, mainly because the pathogenesis of itch in BP remains unclear. Sodium cromoglycate was commonly used in the past as an inhaled drug for the management of bronchial asthma and as an oral treatment for children with urticaria pigmentosa. In this study we sought to assess its efficacy in reducing BP associated itch., Objective: Assessing the efficacy of oral sodium cromoglycate in reducing BP-related pruritus after stabilization of disease activity., Methods: We retrospectively reviewed the medical records of patients with a confirmed diagnosis of BP who were treated with sodium cromoglycate. Patient reported outcome measures (PROM) including: BPDAI pruritus, ABQOL and TABQOL, and BPDAI activity score were compared at two points in time: before commencing treatment with sodium cromoglycate or before commencing maximal dose of this treatment, and at least 4 weeks after treatment commencement., Results: A total of 21 patients met the inclusion criteria. After at least 4 weeks of treatment with oral sodium cromoglycate BPDAI pruritus, ABQOL and TABQOL scores were statistically significantly decreased compared to the scores prior to treatment commencement, P < 0.000, P < 0.008, and P < 0.004, respectively., Discussion: Oral treatment with sodium cromoglycate for the management of pruritus in BP patients may be beneficial, however, further prospective studies are required to better assess its efficacy., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Keller Rosenthal, Boucher and Murrell.)